- Accession Number:
- Form Type:
- Zero Holdings:
- Publication Time:
- 2018-09-19 16:45:25
- Reporting Period:
- Accepted Time:
- 2018-09-19 16:45:25
- SEC Url:
- Form 4 Filing
|Cik||Name||Reported Address||Insider Title||Director||Officer||Large Shareholder||Other|
|1252522||Nicholas Galakatos||C/o Clarus Ventures, Llc |
101 Main Street, Suite 1210
Cambridge MA 02142
|Sec. Name||Acquisiton - Disposition||Date||Amount||Price||Remaning Holdings||Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
|Common Stock||Acquisiton||2018-09-17||162,408||$8.45||4,121,848||No||4||X||Indirect||See footnotes|
|Common Stock||Disposition||2018-09-17||85,823||$15.99||4,036,025||No||4||S||Indirect||See footnotes|
|Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
|Sec. Name||Sec. Type||Acquisiton - Disposition||Date||Amount||Price||Amount - 2||Price - 2|
|Common Stock||Common Stock Warrant (Right to Buy)||Disposition||2018-09-17||162,408||$0.00||162,408||$8.45|
|Remaning Holdings||Exercise Date||Expiration Date||Equity Swap Involved||Transaction Form Type||Transaction Code||Nature of Ownership|
- Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of Clarus Lifesciences II, L.P. ("Clarus"), may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLLC disclaims beneficial ownership of all shares held of record by Clarus in which it does not have an actual pecuniary interest. Each of Nicholas Galakatos, a member of the board of directors, and Messrs. Henner, Liptak, Simon and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus.
- Each of Messrs. Galakatos, Henner, Liptak, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest.
- On September 17, 2018 Clarus Lifesciences II, L.P. ("Clarus") exercised warrants to purchase 162,408 shares of the Company's common stock for $8.448 per share. Clarus paid the exercise price on a cashless basis, resulting in the Company's withholding of 85,823 of the warrant shares to pay the exercise price and issuing to Clarus the remaining 76,585 shares.
- Pursuant to the terms of a Lock-up Agreement executed by the Reporting Person, a member of the board of directors, in favor of the underwriters of the Company's public offering in July 2018 (the "Lock-up"), the Company withheld the number of shares set forth above pursuant to a net settlement permitted under the terms of the Lock-up. No shares were sold by the Reporting Person or Clarus in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of the Lock-up.